Literature DB >> 3544187

Treatment of duodenal ulcer with low-dose antacids.

G Lux, H Hentschel, H G Rohner, H Brunner, K Schütze, P C Lederer, W Rösch.   

Abstract

The aim of the present investigation was to compare the efficacy of a low-dose antacid (Maalox 70, 280 mmol/day) with that of the H2-receptor antagonist cimetidine (Tagamet, 200 mg three times daily and 400 mg/day) after 14 and 28 days in the treatment of duodenal ulcer. The prospective multicentre study included 171 patients with endoscopically confirmed duodenal ulcers. The patients were randomly assigned to the treatment groups with antacid containing Mg and Al hydroxide (M)(4 X 70 mmol/day; n = 86) or to the group receiving cimetidine (T) (1000 mg/day; n = 85). The two treatment groups were matched for age, sex, drinking and smoking habits, and drug use. Endoscopic examinations were carried out before the start of treatment and 14 days later. If the ulcer was still present at this time, the second endoscopic examination was done after a further 14 days. Endoscopically, the ulcer had healed at 14 days in 38.8% (M) and in 34.9% (T) and at 28 days in 80.0% (M) and 74.7% (T), respectively. The healing rate did not differ significantly between the two treatment groups. Complaints, measured as percentage of days per week with upper abdominal pain, were significantly reduced in both groups. No significant differences were found between the two treatment groups with regard to pain relief or side effects. Treatment had to be abandoned in one patient receiving antacid because of diarrhoea and in one patient receiving cimetidine because of the absence of any response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3544187     DOI: 10.3109/00365528608996421

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  Double-blind randomized multicenter study comparing Maalox TC tablets and ranitidine in healing of duodenal ulcers.

Authors:  J O Hunter; R J Walker; J Crowe; R R Gillies; K R Gillies; K R Gough; S Lorber
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer.

Authors:  S K Lam; W M Hui; M M Ng; A S Lok; C L Lai; F Branicki; W Y Lau; G P Poon
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

3.  Risk factors for healing of duodenal ulcer under antacid treatment: do ulcer patients need individual treatment?

Authors:  S Massarrat; H G Müller; P Schmitz-Moormann
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

Review 4.  Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

Authors:  P N Maton; M E Burton
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Antacids and ulcer healing. A review of the evidence.

Authors:  R P Walt; M J Langman
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 6.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

7.  Comparison of low-dose antacids, cimetidine, and placebo on 24-hour intragastric acidity in healthy volunteers.

Authors:  R Weberg; A Berstad; M Osnes
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

8.  Gastric emptying of two radiolabelled antacids with simultaneous monitoring of gastric pH.

Authors:  J Monés; I Carrio; S Sainz; L Berná; P Clavé; M Liszkay; M Roca; F Vilardell
Journal:  Eur J Nucl Med       Date:  1995-10

Review 9.  Antacids. Indications and limitations.

Authors:  C K Ching; S K Lam
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 10.  Treatment of peptic ulcer disease in the arthritic patient.

Authors:  D Nunes; N P Kennedy; D G Weir
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.